嗜酸性粒细胞在心血管疾病中的研究进展

doi:10.20223/j.cnki.1000-8535.2025.04.001

广州医药 ›› 2025, Vol. 56 ›› Issue (4): 429-438.DOI: 10.20223/j.cnki.1000-8535.2025.04.001

• 专家述评 • 下一篇

嗜酸性粒细胞在心血管疾病中的研究进展

邓智勇, 杨崇哲

华南理工大学附属第二医院（广州市第一人民医院）老年医学科心血管内科（广东广州 510180）

收稿日期:2024-08-26 出版日期:2025-04-20 发布日期:2025-05-07
通讯作者: 杨崇哲,E-mail：eyyangchongzhe@scut.edu.cn
作者简介:杨崇哲医学博士,主任医师,博士研究生导师,博士后合作导师,广州市第一人民医院老年心血管病内科副主任,美国哈佛大学医学院博士后及附属布莱根妇女医院访问学者。中国高血压联盟理事,广东省医师协会高血压专业医师分会副主任委员,广东省医师协会健康管理专委会常务委员,广州市高层次人才青年后备人才。从事心血管及老年疾病专科临床、教学及科研工作20余年,研究方向为心血管免疫学及老年共病的机制和临床诊疗。主持承担国家自然科学基金面上项目、青年项目、广东省自然科学基金、广州市（校）联合重点项目、华南理工大学高校中央高校基本科研项目（自然科学类）等多项科研基金项目,以第一或通讯作者发表Nature Communications,Cardiovascular Research等SCI论文20余篇。
基金资助:
国家自然科学基金（82170234,82400301）

Research progress of eosinophils in cardiovascular diseases

DENG Zhiyong, YANG Chongzhe

Cardiovascular Department of Geriatrics,the Second Affiliated Hospital of South China University of Technology,Guangzhou First People’s Hospital,Guangzhou 510180,China

Received:2024-08-26 Online:2025-04-20 Published:2025-05-07

摘要/Abstract

摘要： 嗜酸性粒细胞（EOS）作为过敏反应中关键的先天免疫细胞,在心血管疾病的发生与发展进程中也扮演着至关重要的角色。大量证据显示,血液EOS计数与诸多心血管疾病之间存在紧密联系,但临床研究得出的结论不尽相同。基础研究发现,EOS一方面可通过释放白细胞介素-4（IL-4）、IL-13及阳离子蛋白等细胞因子,对心肌梗死、心肌肥厚、心力衰竭或腹主动脉瘤发挥保护作用;另一方面,EOS表达的阳离子蛋白和血小板活化因子会促进平滑肌细胞增殖和钙化,进而加速动脉粥样硬化的形成。因此,EOS在不同心血管疾病中所发挥的作用存在差异,这与疾病的演变进程、EOS的数量均密切相关。本文对现有的临床和基础研究成果进行汇总,阐述EOS在各类心血管疾病中的不同作用。

关键词: 嗜酸性粒细胞, 心血管疾病, 阳离子蛋白

Abstract: Eosinophils（EOS）,as key innate immune cells in allergic reactions,play a crucial role in the occurrence and development of cardiovascular diseases．Ample evidence shows that the count of blood EOS is closely related to many cardiovascular diseases．However,the conclusions drawn from clinical studies are inconsistent,and these contradictory observational results still cannot be reasonably explained so far．Basic research has found that,on the one hand,EOS can exert protective effects on myocardial infarction,myocardial hypertrophy,heart failure,or abdominal aortic aneurysm by releasing cytokines such as interleukin-4（IL-4）,IL-13,and cationic proteins;on the other hand,the cationic proteins and platelet activating factors expressed by EOS can promote the proliferation and calcification of smooth muscle cells,thereby accelerating the formation of atherosclerosis．Therefore,the roles played by EOS in different cardiovascular diseases vary,which is closely related to the evolution process of the disease and the number of EOS．This article will summarize the existing clinical and basic research results to elaborate the different roles of EOS in various cardiovascular diseases．

Key words: eosinophils, cardiovascular diseases, cationic protein

邓智勇, 杨崇哲. 嗜酸性粒细胞在心血管疾病中的研究进展[J]. 广州医药, 2025, 56(4): 429-438.

DENG Zhiyong, YANG Chongzhe. Research progress of eosinophils in cardiovascular diseases[J]. Guangzhou Medical Journal, 2025, 56(4): 429-438.

参考文献

[1] HEUSCH G.Myocardial ischaemia-reperfusion injury and cardioprotection in perspective[J].Nat Rev Cardiol,2020,17(12):773-789.
[2] 国家心血管病中心,中国心血管健康与疾病报告编写组,胡盛寿.中国心血管健康与疾病报告2023概要[J].中国循环杂志,2024,39(7):625-660.
[3] ONG S B,HERNANDEZ-RESENDIZ S,CRESPO-AVILAN G E,et al.Inflammation following acute myocardial infarction:Multiple players,dynamic roles,and novel therapeutic opportunities[J].Pharmacol Ther,2018(186):73-87.
[4] KOLOGRIVOVA I,SHTATOLKINA M,SUSLOVA T,et al.Cells of the immune system in cardiac remodeling:Main players in resolution of inflammation and repair after myocardial infarction[J].Front Immunol,2021(12):664457.
[5] KHOURY P,GRAYSON P C,KLION A D.Eosinophils in vasculitis:Characteristics and roles in pathogenesis[J].Nat Rev Rheumatol,2014,10(8):474-483.
[6] WEN T,ROTHENBERG M E.The regulatory function of eosinophils[J].Microbiol Spectr,2016,4(5):10.
[7] DUNN J L M,ROTHENBERG M E.2021 year in review:Spotlight on eosinophils[J].J Allergy Clin Immunol,2022,149(2):517-524.
[8] VALENT P,DEGENFELD-SCHONBURG L,SADOVNIK I,et al.Eosinophils and eosinophil-associated disorders:Immunological,clinical,and molecular complexity[J].Semin Immunopathol,2021,43(3):423-438.
[9] WECHSLER M E,MUNITZ A,ACKERMAN S J,et al.Eosinophils in health and disease:A state-of-the-art review[J].Mayo Clin Proc,2021,96(10):2694-2707.
[10] PONGDEE T,MANEMANN S M,DECKER P A,et al.Rethinking blood eosinophil counts:Epidemiology,associated chronic diseases,and increased risks of cardiovascular disease[J].J Allergy Clin Immunol Glob,2022,1(4):233-240.
[11] SHAH A D,DENAXAS S,NICHOLAS O,et al.Low eosinophil and low lymphocyte counts and the incidence of 12 cardiovascular diseases:A CALIBER cohort study[J].Open Heart,2016,3(2):e000477.
[12] FRANGOGIANNIS N G.The inflammatory response in myocardial injury,repair,and remodelling[J].Nat Rev Cardiol,2014,11(5):255-265.
[13] TIMMERS L,PASTERKAMP G,DE HOOG V C,et al.The innate immune response in reperfused myocardium[J].Cardiovasc Res,2012,94(2):276-283.
[14] LIU J,YANG C,LIU T,et al.Eosinophils improve cardiac function after myocardial infarction[J].Nat Commun,2020,11(1):6396.
[15] ROSENBERG H F,DYER K D,TIFFANY H L,et al.Rapid evolution of a unique family of primate ribonuclease genes[J].Nat Genet,1995,10(2):219-223.
[16] LARSON K A,OLSON E V,MADDEN B J,et al.Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily[J].Proc Natl Acad Sci U S A,1996,93(22):12370-12375.
[17] YANG C,LI J,DENG Z,et al.Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy[J].Cardiovasc Res,2023,119(1):195-212.
[18] DENG Y,WU S,YANG Y,et al.Unique phenotypes of heart resident type 2 innate lymphoid cells[J].Front Immunol,2020(11):802.
[19] YU H,WEI Y,DONG Y,et al.Regulation of Notch signaling pathway to innate lymphoid cells in patients with acute myocardial infarction[J].Immunol Invest,2023,52(2):241-255.
[20] LIU T,MENG Z,LIU J,et al.Group 2 innate lymphoid cells protect mouse heart from myocardial infarction injury via interleukin 5,eosinophils,and dendritic cells[J].Cardiovasc Res,2023,119(4):1046-1061.
[21] DIEDERICHSEN A C,RASMUSSEN L M,SOGAARD R,et al.The Danish Cardiovascular Screening Trial(DANCAVAS):Study protocol for a randomized controlled trial[J].Trials,2015(16):554.
[22] GAO S,DENG Y,WU J,et al.Eosinophils count in peripheral circulation is associated with coronary artery disease[J].Atherosclerosis,2019(286):128-134.
[23] NAKAMURA M,SADOSHIMA J.Mechanisms of physiological and pathological cardiac hypertrophy[J].Nat Rev Cardiol,2018,15(7):387-407.
[24] LEI H,HU J,SUN K,et al.The role and molecular mechanism of epigenetics in cardiac hypertrophy[J].Heart Fail Rev,2021,26(6):1505-1514.
[25] VERDOIA M,SCHAFFER A,CASSETTI E,et al.Absolute eosinophils count and the extent of coronary artery disease:A single centre cohort study[J].J Thromb Thrombolysis,2015,39(4):459-466.
[26] VURAL A,AYDIN E.The predictive value of eosinophil indices for major cardiovascular events in patients with acute decompensated HFrEF[J].Medicina,2022,58(10):1455.
[27] LECHNER K,von SCHACKY C,MCKENZIE A L,et al.Lifestyle factors and high-risk atherosclerosis:Pathways and mechanisms beyond traditional risk factors[J].Eur J Prev Cardiol,2020,27(4):394-406.
[28] GISTERA A,HANSSON G K.The immunology of atherosclerosis[J].Nat Rev Nephrol,2017,13(6):368-380.
[29] MENG Z,ZHANG S,LI W,et al.Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis[J].Eur Heart J,2023,44(29):2763-2783.
[30] MARX C,NOVOTNY J,SALBECK D,et al.Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps[J].Blood,2019,134(21):1859-1872.
[31] TANAKA M,FUKUI M FAU - TOMIYASU K-I,TOMIYASU K FAU - AKABAME S,et al.Eosinophil count is positively correlated with coronary artery calcification[J].Hypertens Res,2012,35(3):325-328.
[32] LEDERLE F A,KYRIAKIDES T C,STROUPE K T,et al.Open versus endovascular repair of abdominal aortic aneurysm[J].N Engl J Med,2019,380(22):2126-2135.
[33] ULLERY B W,HALLETT R L,FLEISCHMANN D.Epidemiology and contemporary management of abdominal aortic aneurysms[J].Abdom Radiol(NY),2018,43(5):1032-1043.
[34] LIU C L,LIU X,ZHANG Y,et al.Eosinophils protect mice from angiotensin-II perfusion-induced abdominal aortic aneurysm[J].Circ Res,2021,128(2):188-202.
[35] ZHANG Y,LIU T,DENG Z,et al.Group 2 innate lymphoid cells protect mice from abdominal aortic aneurysm formation via IL5 and eosinophils[J].Adv Sci,2023,10(7):e2206958.
[36] LANGENSKIOLD M,SMIDFELT K,NORDANSTIG J,et al.Leukocyte subsets and abdominal aortic aneurysms detected by screening in men[J].J Intern Med,2020,288(3):345-355.
[37] VENGE P,BYSTRöM J FAU - CARLSON M,CARLSON M FAU - HâKANSSON L,et al.Eosinophil cationic protein(ECP):Molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease[J].Clin Exp Allergy,1999,29(9):1172-1186.
[38] CHIHARA J,YAMAMOTO T,KURACHI D,et al.Possible release of eosinophil granule proteins in response to signaling from intercellular adhesion molecule-1 and its ligands[J].Int Arch Allergy Immunol,1995,108(Suppl 1):52-54.
[39] de OLIVEIRA P C,de OLIVEIRA LOPES D,do VALE COELHO I E,et al.Cytotoxic activities of eosinophil cationic protein and eosinophil-derived neurotoxin:In silico analysis[J].Cancer Genomics Proteomics,2015,12(6):397-402.
[40] BATTEN D,DYER K D,DOMACHOWSKE J B,et al.Molecular cloning of four novel murine ribonuclease genes:unusual expansion within the ribonuclease A gene family[J].Nucleic Acids Res,1997,25(21):4235-4239.
[41] CAFORIO A L,PANKUWEIT S,ARBUSTINI E,et al.Current state of knowledge on aetiology,diagnosis,management,and therapy of myocarditis:A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J].Eur Heart J,2013,34(33):2648,2648a-2648d.
[42] OAKLEY C M,OLSEN G J.Eosinophilia and heart disease[J].Br Heart J,1977,39(3):233-237.
[43] CUGNO M,MARZANO A V,LORINI M,et al.Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia:A possible link with thrombosis[J].PLoS One,2014,9(11):e111862.
[44] SEGUELA P E,IRIART X,ACAR P,et al.Eosinophilic cardiac disease:Molecular,clinical and imaging aspects[J].Arch Cardiovasc Dis,2015,108(4):258-268.
[45] AKUTHOTA P,WELLER P F.Spectrum of eosinophilic end-organ manifestations[J].Immunol Allergy Clin North Am,2015,35(3):403-411.
[46] XIAO L,HARRISON D G.Inflammation in hypertension[J].Can J Cardiol,2020,36(5):635-647.
[47] APOSTOLOPOULOS V,DE COURTEN M P,STOJANOVSKA L,et al.The complex immunological and inflammatory network of adipose tissue in obesity[J].Mol Nutr Food Res,2016,60(1):43-57.
[48] WITHERS S B,FORMAN R,MEZA-PEREZ S,et al.Eosinophils are key regulators of perivascular adipose tissue and vascular functionality[J].Sci Rep,2017(7):44571.
[49] BENJAMIN E J,LEVY D,VAZIRI S M,et al.Independent risk factors for atrial fibrillation in a population-based cohort.The Framingham Heart Study[J].JAMA,1994,271(11):840-844.
[50] WOLF P A,ABBOTT RD FAU - KANNEL W B,KANNEL W B.Atrial fibrillation as an independent risk factor for stroke:The Framingham Study[J].Stroke,1991,22(8):983-988.
[51] BENJAMIN E J,WOLF P A,D’AGOSTINO R B,et al.Impact of atrial fibrillation on the risk of death:The Framingham Heart Study[J].Circulation,1998,98(10):946-952.
[52] SOLIMAN E Z,SAFFORD M M,MUNTNER P,et al.Atrial fibrillation and the risk of myocardial infarction[J].JAMA Intern Med,2014,174(1):107-114.
[53] MISIALEK J R,BEKWELEM W,CHEN L Y,et al.Association of white blood cell count and differential with the incidence of atrial fibrillation:The atherosclerosis risk in communities(ARIC)study[J].PLoS One,2015,10(8):e0136219.

嗜酸性粒细胞在心血管疾病中的研究进展

Research progress of eosinophils in cardiovascular diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	朱怡怡, 杨婵, 王振兴. 全身免疫炎症指数与心血管疾病相关研究进展[J]. 广州医药, 2024, 55(9): 985-990.
[2]	王慧, 张新顺, 邢朝品, 谢庆芝. 儿童嗜酸细胞性胃肠炎的临床诊治分析[J]. 广州医药, 2024, 55(9): 1027-1032.
[3]	董顺雨, 张态. 斑马鱼心血管疾病模型研究进展[J]. 广州医药, 2024, 55(3): 231-235.
[4]	高雅婷, 邱对鑫, 高磊, 石开虎. Wnt/β-catenin信号通路在心肌纤维化中的作用研究进展[J]. 广州医药, 2024, 55(1): 85-90.
[5]	胡桂崧. 老年心血管疾病患者膳食行为改善的影响因素[J]. 广州医药, 2023, 54(11): 95-99.
[6]	谢育坤, 王阳顺, 徐鹏, 吴向红, 郭耀光, 郑艳辉. 载脂蛋白E基因多态性、血清ApoE浓度与精神分裂症患者心血管疾病风险的相关性[J]. 广州医药, 2020, 51(5): 135-137.
[7]	谢育坤, 宁婷, 徐鹏, 吴向红, 郭耀光, 郑艳辉, 王阳顺. MTHFR C677T基因多态性、血浆HCY水平与精神分裂症患者心血管风险的相关性[J]. 广州医药, 2020, 51(1): 109-112.
[8]	周道祥, 丘卫恩, 周淑英. 血浆BNP预测急性肺栓塞患者发生心血管疾病的临床研究[J]. 广州医药, 2019, 50(2): 20-23.